July 2019- Volume 15, Issue 7
In this Issue
Business & Government Policy
Patent Docs: BIO International Convention wrap-up
Patent Docs: BIO International Convention wrap-up
Kevin Noonan, a partner with the law firm McDonnell Boehnen Hulbert & Berghoff LLP and founding author of the Patent Docs weblog, recaps the highlights of the latest annual BIO meeting
AbbVie makes $63B play for Allergan
AbbVie makes $63B play for Allergan
Proposed acquisition is said to be a ‘tranformative’ move for both companies
On the cutting edge
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Advancing biologics
Advancing biologics
FDA takes new step to help advance the transition of certain biological products
New mass spec for Thermo
New mass spec for Thermo
Thermo Fisher Scientific acquires Slovakian mass spec software firm HighChem
Discovery
Big agreements for Atomwise
Big agreements for Atomwise
Atomwise announces deals with Eli Lilly and Enamine
A better picture of how antibiotics kill
A better picture of how antibiotics kill
Machine learning reveals metabolic pathways disrupted by the drugs
Accelerating antibiotics
Accelerating antibiotics
Polyphor and the University of Zurich examine new class of drugs inhibiting the LPS transport pathway
Gilead, Goldfinch take aim at kidney disease
Gilead, Goldfinch take aim at kidney disease
All told, the total deal value could reach over $2B if all milestones are met
Working to ‘develop tomorrow’s drugs’
Working to ‘develop tomorrow’s drugs’
GSK, University of California to establish new lab for genetic and CRISPR research
Research & Development
Amicus-Penn collaboration gains new life
Amicus-Penn collaboration gains new life
Partners have expanded their agreement to include new indications and new research programs
Collaboration center
Collaboration center
Platform will help to characterize biotherapeutic products
A need for diversity
A need for diversity
Study finds that over 75 percent of genomic data is of European origin
A banner day for modeling
A banner day for modeling
Q2 saw encouraging advances in disease modeling options
Meet the Mini-Brain
Meet the Mini-Brain
AxoSim licenses revolutionary Mini-Brain technology from Johns Hopkins
Diagnostics
Double duty for ingestible technology
Double duty for ingestible technology
Micro-bio-electronic device might be able to diagnose and treat GI problems
A stool test for cirrhosis
A stool test for cirrhosis
UC San Diego researchers analyze stool microbes to diagnose liver disease
ADDF commits $50M to early AD detection
ADDF commits $50M to early AD detection
Alzheimer’s Drug Discovery Foundation aims to fast-track digital tools for the disease
‘Liquid’ assets
‘Liquid’ assets
A look at a recent FDA decision and analyst forecasts in the field of liquid biopsy
Clinical Trials
If at first you don't succeed...
If at first you don't succeed...
Despite setback with IFX-1, InflaRx continues testing
Imago unveils IMG-7289
Imago unveils IMG-7289
Safety and efficacy data informs expansion of study into Phase 2b
Design in the cloud
Design in the cloud
Exploristics announces launch of KerusCloud 2.0
A faster track for flu vaccine
A faster track for flu vaccine
Novavax confirms accelerated approval pathway available for licensure of NanoFlu
A new network
A new network
National Kidney Foundation introduces its plan for an expansive kidney disease registry
Preclinical
Stem-ulating research
Stem-ulating research
Two branches of stem cell research discover the impact on both diabetes and cardiac damage
Potential to treat Pompe disease
Potential to treat Pompe disease
Findings validate gene therapy approach
Immunotherapies vs. infections
Immunotherapies vs. infections
Breakthrough research identifies a potential vaccine against deadly fungus
The rodents shall remain
The rodents shall remain
Rats and mice expected to continue as most lucrative species for animal models
Contract Services
Charles River cultivates change
Charles River cultivates change
Charles River constructs new collaborative science partnerships
Aldevron adds space
Aldevron adds space
Biologics manufacturer expands and names new business heads
Marking an anniversary
Marking an anniversary
BioAscent records successful first year as fully integrated discovery services CRO
Special Reports
Special Report on Drug Screening: Phenotypic finery
Special Report on Drug Screening: Phenotypic finery
Microscopy meets the molecular in the search for phenotypic impacts in drug screening
Feature
Focus Feature on Cancer Research News: Hitting the target
Focus Feature on Cancer Research News: Hitting the target
It’s never just been about killing or removing tumors; it’s about aiming at them accurately
Commentary
Guest Commentary: ACT clinical trials--The long road
Guest Commentary: ACT clinical trials--The long road
As excitement and investment related to adoptive cell transfer products increases, there are concerns and issues that need to be addressed in terms of long-term follow-up trials
Out of order: Inverted focus?
Out of order: Inverted focus?
Our microbiomes might adversely influence some therapeutics that we take, but does that mean that we should be altering the microbiome to compensate?
Editor's Focus
Editor’s focus: Off-target effect from inactives?
Editor’s focus: Off-target effect from inactives?
More information about adverse effects of so-called 'inactive' ingredients could be useful, but it also could just be a ton more information that we can't do much with once we have it
